CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 88 filers reported holding CUREVAC N V in Q2 2024. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2 | 0.0% | 697 | 0.0% | 0.00% | – |
| Q1 2024 | $2 | -33.3% | 697 | 0.0% | 0.00% | – |
| Q4 2023 | $3 | -40.0% | 697 | 0.0% | 0.00% | – |
| Q3 2023 | $5 | -28.6% | 697 | 0.0% | 0.00% | – |
| Q2 2023 | $7 | -85.4% | 697 | -89.9% | 0.00% | – |
| Q1 2023 | $48 | +41.2% | 6,912 | +21.4% | 0.00% | – |
| Q4 2022 | $34 | -99.9% | 5,692 | -7.8% | 0.00% | – |
| Q3 2022 | $49,000 | -44.3% | 6,171 | -4.3% | 0.00% | -100.0% |
| Q2 2022 | $88,000 | +700.0% | 6,450 | +1083.5% | 0.00% | – |
| Q1 2022 | $11,000 | -42.1% | 545 | 0.0% | 0.00% | – |
| Q4 2021 | $19,000 | -93.5% | 545 | -86.4% | 0.00% | -100.0% |
| Q2 2021 | $294,000 | -10.1% | 4,006 | +12.2% | 0.00% | 0.0% |
| Q1 2021 | $327,000 | – | 3,571 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 370,385 | $17,241,000 | 4.81% |
| Novo Holdings A/S | 201,642 | $9,386,000 | 0.47% |
| Vivo Capital, LLC | 169,825 | $7,905,000 | 0.46% |
| Baillie Gifford | 3,896,475 | $181,381,000 | 0.12% |
| DekaBank Deutsche Girozentrale | 435,500 | $21,707,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 69,176 | $3,220,000 | 0.08% |
| HHLR ADVISORS, LTD. | 186,183 | $8,667,000 | 0.07% |
| Pinz Capital Management, LP | 3,600 | $168,000 | 0.06% |
| Cutler Group LLC / CA | 18,400 | $856,000 | 0.05% |
| ETF MANAGERS GROUP, LLC | 35,722 | $1,632,000 | 0.05% |